Biorestorative Therapies, Inc. (BRTX)
NASDAQ:BRTX
Want to see BRTX full AI Analyst Report?
BRTX Stock Chart & Stats
$1.18
-$0.13(-7.22%)
At close: 4:00 PM EST
$1.18
-$0.13(-7.22%)
Day’s Range― - ―
52-Week Range$0.16 - $1.89
Previous CloseN/A
Volume34.37K
Average Volume (3M)20.77M
Market Cap
$10.44M
Enterprise Value$514.34K
Total Cash (Recent Filing)$3.59M
Total Debt (Recent Filing)$34.52K
Price to Earnings (P/E)―
Beta1.22
Next Earnings
Aug 18, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.23
Shares Outstanding25,478,170
10 Day Avg. Volume1,108,557
30 Day Avg. Volume20,767,964
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)29.75
Price to Sales (P/S)29.50
P/FCF Ratio-0.97
Enterprise Value/Market Cap0.05
Enterprise Value/Revenue1.44
Enterprise Value/Gross Profit1.56
Enterprise Value/Ebitda-0.05
Forecast
1Y Price Target
$8.00Price Target Upside577.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.5
Revenue Forecast (FY)$1.90M
Bulls Say, Bears Say
Bulls Say
Low LeverageNear-zero reported debt meaningfully lowers interest burden and reduces bankruptcy risk, preserving financial optionality. For a development-stage biotech this durable low-leverage profile supports funding flexibility for R&D and strategic partnerships without immediate debt servicing pressure.
Attractive Gross MarginA TTM gross margin around 63% suggests favorable underlying unit economics for product-related revenue. If management can scale commercial execution and contain operating expenses, these margins offer a credible path to profitability as fixed R&D and G&A are spread over higher sales volumes.
Management Continuity & Commercial HireMulti-year extensions for CEO and CFO plus a dedicated VP for biocosmeceuticals strengthen leadership continuity and commercial capability. Stable senior management and an explicit commercial hire support consistent R&D oversight and early go-to-market execution over the medium term.
Bears Say
Heavy Cash BurnSustained negative operating and free cash flow near $11.8–11.9M TTM means the business consistently consumes capital faster than it generates it. This durable cash-burn profile forces repeated external financing, heightens dilution risk and can limit investments in clinical programs absent a clear revenue inflection.
Minimal And Declining RevenueAn extremely small revenue base (~$0.36M) combined with a sharp YoY decline undermines the firm’s ability to cover fixed costs or meaningfully fund development. The shrinking top line increases dependency on financings and raises execution risk for commercialization plans over the coming months.
High-cost Loan And Lender InfluenceA 12% revolving facility with lender-appointed directors increases cost of capital and governance risk. Higher interest expense and potential restrictive covenants can constrain strategic flexibility, create operational pressure, and elevate the probability of additional dilutive financing or onerous deal terms.
BioRestorative Therapies News
BRTX FAQ
What was Biorestorative Therapies, Inc.’s price range in the past 12 months?
Biorestorative Therapies, Inc. lowest stock price was $0.16 and its highest was $1.89 in the past 12 months.
What is Biorestorative Therapies, Inc.’s market cap?
Biorestorative Therapies, Inc.’s market cap is $10.44M.
When is Biorestorative Therapies, Inc.’s upcoming earnings report date?
Biorestorative Therapies, Inc.’s upcoming earnings report date is Aug 18, 2026 which is in 60 days.
How were Biorestorative Therapies, Inc.’s earnings last quarter?
Biorestorative Therapies, Inc. released its earnings results on May 20, 2026. The company reported -$0.2 earnings per share for the quarter, the consensus estimate of -$0.2 by $0.
Is Biorestorative Therapies, Inc. overvalued?
According to Wall Street analysts Biorestorative Therapies, Inc.’s price is currently Undervalued.
Does Biorestorative Therapies, Inc. pay dividends?
Biorestorative Therapies, Inc. does not currently pay dividends.
What is Biorestorative Therapies, Inc.’s EPS estimate?
Biorestorative Therapies, Inc.’s EPS estimate is -0.13.
How many shares outstanding does Biorestorative Therapies, Inc. have?
Biorestorative Therapies, Inc. has 25,478,170 shares outstanding.
What happened to Biorestorative Therapies, Inc.’s price movement after its last earnings report?
Biorestorative Therapies, Inc. reported an EPS of -$0.2 in its last earnings report, expectations of -$0.2. Following the earnings report the stock price went down -7.65%.
Which hedge fund is a major shareholder of Biorestorative Therapies, Inc.?
Currently, no hedge funds are holding shares in BRTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biorestorative Therapies, Inc.
BioRestorative Therapies, Inc. is a life sciences company dedicated to developing regenerative medicine products and therapies. Their approach primarily utilizes adult stem cell protocols to address two key areas: disc/spine disease and metabolic disorders. Within their disc/spine program, known as brtxDisc, the company's leading cell therapy candidate is BRTX-100. This treatment involves culturing mesenchymal stem cells harvested from a patient's own bone marrow (autologous) to provide a non-surgical solution for painful lumbosacral disc conditions. BRTX-100 has successfully completed Phase 1 clinical trials. The company is also advancing its Metabolic Program, named ThermoStem, which is currently in the preclinical stage. This cell-based therapy targets obesity and other metabolic ailments by employing brown adipose-derived stem cells to generate brown adipose tissue. Beyond these core programs, BioRestorative Therapies also offers an investigational curved needle device designed for delivering cells and various therapeutic materials to the spine and discs. The company fosters strategic research and development partnerships, including agreements with Rohto Pharmaceutical Co., Ltd., Pfizer, Inc., and the University of Pennsylvania. Founded in 1997 and headquartered in Melville, New York, the company was initially known as Stem Cell Assurance, Inc., before rebranding to BioRestorative Therapies, Inc. in August 2011.
BRTX Stock 12 Month Forecast
Average Price Target
$8.00
▲(577.97% Upside)
Technical Analysis
Cellectar Biosciences
―
Marker Therapeutics
―
Cocrystal Pharma
―
Sensei Biotherapeutics
―
AEON Biopharma
―
Ownership Overview
1.46% Insiders
0.22% Mutual Funds
0.16% Other Institutional Investors
98.17% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---